nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—CYP1B1—Progesterone—uterine cancer	0.123	0.185	CbGbCtD
Lansoprazole—CYP1A1—Progesterone—uterine cancer	0.0541	0.0812	CbGbCtD
Lansoprazole—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.0471	0.0708	CbGbCtD
Lansoprazole—ABCG2—Dactinomycin—uterine cancer	0.0465	0.0698	CbGbCtD
Lansoprazole—CYP1B1—Doxorubicin—uterine cancer	0.0376	0.0565	CbGbCtD
Lansoprazole—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0329	0.0494	CbGbCtD
Lansoprazole—ABCG2—Carboplatin—uterine cancer	0.0312	0.0469	CbGbCtD
Lansoprazole—CYP2C8—Progesterone—uterine cancer	0.0312	0.0469	CbGbCtD
Lansoprazole—ABCG2—Etoposide—uterine cancer	0.0262	0.0394	CbGbCtD
Lansoprazole—CYP2C19—Progesterone—uterine cancer	0.0262	0.0393	CbGbCtD
Lansoprazole—CYP1A2—Progesterone—uterine cancer	0.0242	0.0363	CbGbCtD
Lansoprazole—CYP2C9—Progesterone—uterine cancer	0.0218	0.0327	CbGbCtD
Lansoprazole—ABCB1—Progesterone—uterine cancer	0.0211	0.0317	CbGbCtD
Lansoprazole—CYP2D6—Progesterone—uterine cancer	0.0199	0.0299	CbGbCtD
Lansoprazole—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0191	0.0287	CbGbCtD
Lansoprazole—ABCG2—Doxorubicin—uterine cancer	0.0179	0.0269	CbGbCtD
Lansoprazole—ABCB1—Dactinomycin—uterine cancer	0.0168	0.0252	CbGbCtD
Lansoprazole—CYP2C8—Etoposide—uterine cancer	0.014	0.021	CbGbCtD
Lansoprazole—CYP3A4—Progesterone—uterine cancer	0.0127	0.019	CbGbCtD
Lansoprazole—CYP1A2—Etoposide—uterine cancer	0.0108	0.0162	CbGbCtD
Lansoprazole—ABCB1—Etoposide—uterine cancer	0.00946	0.0142	CbGbCtD
Lansoprazole—ABCB1—Doxorubicin—uterine cancer	0.00645	0.00969	CbGbCtD
Lansoprazole—CYP2D6—Doxorubicin—uterine cancer	0.00608	0.00913	CbGbCtD
Lansoprazole—CYP3A4—Etoposide—uterine cancer	0.00567	0.00851	CbGbCtD
Lansoprazole—CYP3A4—Doxorubicin—uterine cancer	0.00387	0.0058	CbGbCtD
Lansoprazole—Omeprazole—CYP11A1—uterine cancer	0.00262	1	CrCbGaD
Lansoprazole—CYP4A11—renal system—uterine cancer	0.00218	0.0647	CbGeAlD
Lansoprazole—ATP4A—epithelium—uterine cancer	0.00189	0.0562	CbGeAlD
Lansoprazole—ATP4A—renal system—uterine cancer	0.00175	0.0522	CbGeAlD
Lansoprazole—CYP4A11—vagina—uterine cancer	0.00158	0.0469	CbGeAlD
Lansoprazole—CYP2C18—uterine cervix—uterine cancer	0.00154	0.0458	CbGeAlD
Lansoprazole—ATP4A—female reproductive system—uterine cancer	0.00141	0.0418	CbGeAlD
Lansoprazole—CYP2C18—mammalian vulva—uterine cancer	0.00135	0.0401	CbGeAlD
Lansoprazole—MAPT—lymph node—uterine cancer	0.00111	0.0329	CbGeAlD
Lansoprazole—CYP2C18—vagina—uterine cancer	0.00104	0.0311	CbGeAlD
Lansoprazole—CYP1B1—smooth muscle tissue—uterine cancer	0.000726	0.0216	CbGeAlD
Lansoprazole—ABCG2—myometrium—uterine cancer	0.000715	0.0212	CbGeAlD
Lansoprazole—CYP1B1—decidua—uterine cancer	0.000712	0.0212	CbGeAlD
Lansoprazole—CYP1B1—renal system—uterine cancer	0.000699	0.0208	CbGeAlD
Lansoprazole—CYP1B1—uterus—uterine cancer	0.000622	0.0185	CbGeAlD
Lansoprazole—CYP1B1—female reproductive system—uterine cancer	0.00056	0.0166	CbGeAlD
Lansoprazole—ABCG2—uterine cervix—uterine cancer	0.000556	0.0165	CbGeAlD
Lansoprazole—CYP2C8—renal system—uterine cancer	0.000535	0.0159	CbGeAlD
Lansoprazole—CYP1A1—epithelium—uterine cancer	0.000532	0.0158	CbGeAlD
Lansoprazole—ABCG2—decidua—uterine cancer	0.00053	0.0158	CbGeAlD
Lansoprazole—CYP1A1—uterine cervix—uterine cancer	0.000528	0.0157	CbGeAlD
Lansoprazole—CYP2C8—endometrium—uterine cancer	0.000517	0.0154	CbGeAlD
Lansoprazole—CYP1B1—female gonad—uterine cancer	0.000509	0.0151	CbGeAlD
Lansoprazole—ABCG2—endometrium—uterine cancer	0.000503	0.015	CbGeAlD
Lansoprazole—CYP1A2—renal system—uterine cancer	0.000501	0.0149	CbGeAlD
Lansoprazole—CYP1A1—renal system—uterine cancer	0.000494	0.0147	CbGeAlD
Lansoprazole—ABCG2—mammalian vulva—uterine cancer	0.000487	0.0145	CbGeAlD
Lansoprazole—ABCG2—uterus—uterine cancer	0.000463	0.0138	CbGeAlD
Lansoprazole—CYP1A1—mammalian vulva—uterine cancer	0.000462	0.0137	CbGeAlD
Lansoprazole—CYP2C19—vagina—uterine cancer	0.000444	0.0132	CbGeAlD
Lansoprazole—CYP1A1—uterus—uterine cancer	0.00044	0.0131	CbGeAlD
Lansoprazole—CYP2C8—female reproductive system—uterine cancer	0.000428	0.0127	CbGeAlD
Lansoprazole—CYP1A1—female reproductive system—uterine cancer	0.000396	0.0118	CbGeAlD
Lansoprazole—CYP2C8—vagina—uterine cancer	0.000388	0.0115	CbGeAlD
Lansoprazole—CYP2C9—female reproductive system—uterine cancer	0.000381	0.0113	CbGeAlD
Lansoprazole—ABCG2—female gonad—uterine cancer	0.000379	0.0113	CbGeAlD
Lansoprazole—ABCG2—vagina—uterine cancer	0.000377	0.0112	CbGeAlD
Lansoprazole—CYP3A4—renal system—uterine cancer	0.000362	0.0108	CbGeAlD
Lansoprazole—CYP1A1—female gonad—uterine cancer	0.00036	0.0107	CbGeAlD
Lansoprazole—CYP1A1—vagina—uterine cancer	0.000358	0.0106	CbGeAlD
Lansoprazole—CYP2D6—renal system—uterine cancer	0.000357	0.0106	CbGeAlD
Lansoprazole—ABCB1—myometrium—uterine cancer	0.000352	0.0105	CbGeAlD
Lansoprazole—CYP1B1—lymph node—uterine cancer	0.000327	0.00973	CbGeAlD
Lansoprazole—CYP3A4—female reproductive system—uterine cancer	0.00029	0.00863	CbGeAlD
Lansoprazole—CYP2D6—female reproductive system—uterine cancer	0.000286	0.00849	CbGeAlD
Lansoprazole—ABCB1—epithelium—uterine cancer	0.000277	0.00822	CbGeAlD
Lansoprazole—ABCB1—uterine cervix—uterine cancer	0.000274	0.00815	CbGeAlD
Lansoprazole—ABCB1—decidua—uterine cancer	0.000261	0.00777	CbGeAlD
Lansoprazole—CYP2D6—female gonad—uterine cancer	0.00026	0.00773	CbGeAlD
Lansoprazole—ABCB1—renal system—uterine cancer	0.000257	0.00763	CbGeAlD
Lansoprazole—ABCB1—endometrium—uterine cancer	0.000248	0.00737	CbGeAlD
Lansoprazole—ABCG2—lymph node—uterine cancer	0.000244	0.00725	CbGeAlD
Lansoprazole—ABCB1—mammalian vulva—uterine cancer	0.00024	0.00713	CbGeAlD
Lansoprazole—CYP1A1—lymph node—uterine cancer	0.000231	0.00688	CbGeAlD
Lansoprazole—ABCB1—uterus—uterine cancer	0.000229	0.00679	CbGeAlD
Lansoprazole—ABCB1—female reproductive system—uterine cancer	0.000205	0.00611	CbGeAlD
Lansoprazole—ABCB1—female gonad—uterine cancer	0.000187	0.00556	CbGeAlD
Lansoprazole—ABCB1—vagina—uterine cancer	0.000186	0.00552	CbGeAlD
Lansoprazole—ABCB1—lymph node—uterine cancer	0.00012	0.00357	CbGeAlD
Lansoprazole—Asthma—Doxorubicin—uterine cancer	9.06e-05	0.000394	CcSEcCtD
Lansoprazole—Dysphagia—Doxorubicin—uterine cancer	9.06e-05	0.000394	CcSEcCtD
Lansoprazole—Pollakiuria—Epirubicin—uterine cancer	9.05e-05	0.000393	CcSEcCtD
Lansoprazole—Eosinophilia—Doxorubicin—uterine cancer	8.97e-05	0.00039	CcSEcCtD
Lansoprazole—Photosensitivity reaction—Epirubicin—uterine cancer	8.94e-05	0.000388	CcSEcCtD
Lansoprazole—Paraesthesia—Etoposide—uterine cancer	8.92e-05	0.000388	CcSEcCtD
Lansoprazole—Weight increased—Epirubicin—uterine cancer	8.91e-05	0.000387	CcSEcCtD
Lansoprazole—Pancreatitis—Doxorubicin—uterine cancer	8.89e-05	0.000386	CcSEcCtD
Lansoprazole—Dyspnoea—Etoposide—uterine cancer	8.86e-05	0.000385	CcSEcCtD
Lansoprazole—Hyperglycaemia—Epirubicin—uterine cancer	8.84e-05	0.000384	CcSEcCtD
Lansoprazole—Somnolence—Etoposide—uterine cancer	8.83e-05	0.000384	CcSEcCtD
Lansoprazole—Angina pectoris—Doxorubicin—uterine cancer	8.83e-05	0.000384	CcSEcCtD
Lansoprazole—Pneumonia—Epirubicin—uterine cancer	8.78e-05	0.000382	CcSEcCtD
Lansoprazole—Infestation NOS—Epirubicin—uterine cancer	8.73e-05	0.000379	CcSEcCtD
Lansoprazole—Infestation—Epirubicin—uterine cancer	8.73e-05	0.000379	CcSEcCtD
Lansoprazole—Vomiting—Dactinomycin—uterine cancer	8.73e-05	0.000379	CcSEcCtD
Lansoprazole—Bronchitis—Doxorubicin—uterine cancer	8.72e-05	0.000379	CcSEcCtD
Lansoprazole—Stevens-Johnson syndrome—Epirubicin—uterine cancer	8.66e-05	0.000376	CcSEcCtD
Lansoprazole—Rash—Dactinomycin—uterine cancer	8.66e-05	0.000376	CcSEcCtD
Lansoprazole—Decreased appetite—Etoposide—uterine cancer	8.64e-05	0.000375	CcSEcCtD
Lansoprazole—Pancytopenia—Doxorubicin—uterine cancer	8.61e-05	0.000374	CcSEcCtD
Lansoprazole—Renal failure—Epirubicin—uterine cancer	8.58e-05	0.000373	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Etoposide—uterine cancer	8.58e-05	0.000373	CcSEcCtD
Lansoprazole—Fatigue—Etoposide—uterine cancer	8.57e-05	0.000372	CcSEcCtD
Lansoprazole—Neuropathy peripheral—Epirubicin—uterine cancer	8.56e-05	0.000372	CcSEcCtD
Lansoprazole—Stomatitis—Epirubicin—uterine cancer	8.51e-05	0.00037	CcSEcCtD
Lansoprazole—Jaundice—Epirubicin—uterine cancer	8.51e-05	0.00037	CcSEcCtD
Lansoprazole—Pain—Etoposide—uterine cancer	8.5e-05	0.000369	CcSEcCtD
Lansoprazole—Constipation—Etoposide—uterine cancer	8.5e-05	0.000369	CcSEcCtD
Lansoprazole—Urinary tract infection—Epirubicin—uterine cancer	8.49e-05	0.000369	CcSEcCtD
Lansoprazole—Conjunctivitis—Epirubicin—uterine cancer	8.49e-05	0.000369	CcSEcCtD
Lansoprazole—Neutropenia—Doxorubicin—uterine cancer	8.47e-05	0.000368	CcSEcCtD
Lansoprazole—Dysuria—Doxorubicin—uterine cancer	8.47e-05	0.000368	CcSEcCtD
Lansoprazole—Upper respiratory tract infection—Doxorubicin—uterine cancer	8.42e-05	0.000366	CcSEcCtD
Lansoprazole—Sweating—Epirubicin—uterine cancer	8.37e-05	0.000364	CcSEcCtD
Lansoprazole—Pollakiuria—Doxorubicin—uterine cancer	8.37e-05	0.000364	CcSEcCtD
Lansoprazole—Haematuria—Epirubicin—uterine cancer	8.33e-05	0.000362	CcSEcCtD
Lansoprazole—Photosensitivity reaction—Doxorubicin—uterine cancer	8.27e-05	0.000359	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Epirubicin—uterine cancer	8.26e-05	0.000359	CcSEcCtD
Lansoprazole—Weight increased—Doxorubicin—uterine cancer	8.25e-05	0.000358	CcSEcCtD
Lansoprazole—Epistaxis—Epirubicin—uterine cancer	8.24e-05	0.000358	CcSEcCtD
Lansoprazole—Sinusitis—Epirubicin—uterine cancer	8.19e-05	0.000356	CcSEcCtD
Lansoprazole—Feeling abnormal—Etoposide—uterine cancer	8.19e-05	0.000356	CcSEcCtD
Lansoprazole—Hyperglycaemia—Doxorubicin—uterine cancer	8.17e-05	0.000355	CcSEcCtD
Lansoprazole—Nausea—Dactinomycin—uterine cancer	8.15e-05	0.000354	CcSEcCtD
Lansoprazole—Agranulocytosis—Epirubicin—uterine cancer	8.15e-05	0.000354	CcSEcCtD
Lansoprazole—Pneumonia—Doxorubicin—uterine cancer	8.13e-05	0.000353	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Etoposide—uterine cancer	8.13e-05	0.000353	CcSEcCtD
Lansoprazole—Infestation NOS—Doxorubicin—uterine cancer	8.08e-05	0.000351	CcSEcCtD
Lansoprazole—Infestation—Doxorubicin—uterine cancer	8.08e-05	0.000351	CcSEcCtD
Lansoprazole—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	8.01e-05	0.000348	CcSEcCtD
Lansoprazole—Bradycardia—Epirubicin—uterine cancer	7.98e-05	0.000347	CcSEcCtD
Lansoprazole—Renal failure—Doxorubicin—uterine cancer	7.94e-05	0.000345	CcSEcCtD
Lansoprazole—Neuropathy peripheral—Doxorubicin—uterine cancer	7.92e-05	0.000344	CcSEcCtD
Lansoprazole—Urticaria—Etoposide—uterine cancer	7.89e-05	0.000343	CcSEcCtD
Lansoprazole—Jaundice—Doxorubicin—uterine cancer	7.88e-05	0.000342	CcSEcCtD
Lansoprazole—Stomatitis—Doxorubicin—uterine cancer	7.88e-05	0.000342	CcSEcCtD
Lansoprazole—Rhinitis—Epirubicin—uterine cancer	7.86e-05	0.000341	CcSEcCtD
Lansoprazole—Body temperature increased—Etoposide—uterine cancer	7.85e-05	0.000341	CcSEcCtD
Lansoprazole—Abdominal pain—Etoposide—uterine cancer	7.85e-05	0.000341	CcSEcCtD
Lansoprazole—Conjunctivitis—Doxorubicin—uterine cancer	7.85e-05	0.000341	CcSEcCtD
Lansoprazole—Urinary tract infection—Doxorubicin—uterine cancer	7.85e-05	0.000341	CcSEcCtD
Lansoprazole—Hepatitis—Epirubicin—uterine cancer	7.84e-05	0.000341	CcSEcCtD
Lansoprazole—Hypoaesthesia—Epirubicin—uterine cancer	7.8e-05	0.000339	CcSEcCtD
Lansoprazole—Pharyngitis—Epirubicin—uterine cancer	7.78e-05	0.000338	CcSEcCtD
Lansoprazole—Sweating—Doxorubicin—uterine cancer	7.75e-05	0.000337	CcSEcCtD
Lansoprazole—Urinary tract disorder—Epirubicin—uterine cancer	7.74e-05	0.000336	CcSEcCtD
Lansoprazole—Oedema peripheral—Epirubicin—uterine cancer	7.72e-05	0.000336	CcSEcCtD
Lansoprazole—Haematuria—Doxorubicin—uterine cancer	7.7e-05	0.000335	CcSEcCtD
Lansoprazole—Connective tissue disorder—Epirubicin—uterine cancer	7.7e-05	0.000335	CcSEcCtD
Lansoprazole—Urethral disorder—Epirubicin—uterine cancer	7.68e-05	0.000334	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Doxorubicin—uterine cancer	7.64e-05	0.000332	CcSEcCtD
Lansoprazole—Epistaxis—Doxorubicin—uterine cancer	7.62e-05	0.000331	CcSEcCtD
Lansoprazole—Sinusitis—Doxorubicin—uterine cancer	7.58e-05	0.000329	CcSEcCtD
Lansoprazole—Visual impairment—Epirubicin—uterine cancer	7.56e-05	0.000328	CcSEcCtD
Lansoprazole—Agranulocytosis—Doxorubicin—uterine cancer	7.54e-05	0.000328	CcSEcCtD
Lansoprazole—Erythema multiforme—Epirubicin—uterine cancer	7.41e-05	0.000322	CcSEcCtD
Lansoprazole—Bradycardia—Doxorubicin—uterine cancer	7.38e-05	0.000321	CcSEcCtD
Lansoprazole—Eye disorder—Epirubicin—uterine cancer	7.33e-05	0.000318	CcSEcCtD
Lansoprazole—Hypersensitivity—Etoposide—uterine cancer	7.32e-05	0.000318	CcSEcCtD
Lansoprazole—Tinnitus—Epirubicin—uterine cancer	7.31e-05	0.000318	CcSEcCtD
Lansoprazole—Cardiac disorder—Epirubicin—uterine cancer	7.28e-05	0.000316	CcSEcCtD
Lansoprazole—Rhinitis—Doxorubicin—uterine cancer	7.27e-05	0.000316	CcSEcCtD
Lansoprazole—Hepatitis—Doxorubicin—uterine cancer	7.25e-05	0.000315	CcSEcCtD
Lansoprazole—Hypoaesthesia—Doxorubicin—uterine cancer	7.22e-05	0.000314	CcSEcCtD
Lansoprazole—Pharyngitis—Doxorubicin—uterine cancer	7.2e-05	0.000313	CcSEcCtD
Lansoprazole—Urinary tract disorder—Doxorubicin—uterine cancer	7.16e-05	0.000311	CcSEcCtD
Lansoprazole—Oedema peripheral—Doxorubicin—uterine cancer	7.15e-05	0.00031	CcSEcCtD
Lansoprazole—Asthenia—Etoposide—uterine cancer	7.13e-05	0.00031	CcSEcCtD
Lansoprazole—Connective tissue disorder—Doxorubicin—uterine cancer	7.13e-05	0.00031	CcSEcCtD
Lansoprazole—Angiopathy—Epirubicin—uterine cancer	7.11e-05	0.000309	CcSEcCtD
Lansoprazole—Urethral disorder—Doxorubicin—uterine cancer	7.11e-05	0.000309	CcSEcCtD
Lansoprazole—Immune system disorder—Epirubicin—uterine cancer	7.08e-05	0.000308	CcSEcCtD
Lansoprazole—Mediastinal disorder—Epirubicin—uterine cancer	7.07e-05	0.000307	CcSEcCtD
Lansoprazole—Chills—Epirubicin—uterine cancer	7.03e-05	0.000306	CcSEcCtD
Lansoprazole—Pruritus—Etoposide—uterine cancer	7.03e-05	0.000305	CcSEcCtD
Lansoprazole—Arrhythmia—Epirubicin—uterine cancer	7e-05	0.000304	CcSEcCtD
Lansoprazole—Visual impairment—Doxorubicin—uterine cancer	6.99e-05	0.000304	CcSEcCtD
Lansoprazole—Alopecia—Epirubicin—uterine cancer	6.93e-05	0.000301	CcSEcCtD
Lansoprazole—Mental disorder—Epirubicin—uterine cancer	6.87e-05	0.000298	CcSEcCtD
Lansoprazole—Erythema multiforme—Doxorubicin—uterine cancer	6.86e-05	0.000298	CcSEcCtD
Lansoprazole—Malnutrition—Epirubicin—uterine cancer	6.82e-05	0.000296	CcSEcCtD
Lansoprazole—Erythema—Epirubicin—uterine cancer	6.82e-05	0.000296	CcSEcCtD
Lansoprazole—Diarrhoea—Etoposide—uterine cancer	6.8e-05	0.000295	CcSEcCtD
Lansoprazole—Eye disorder—Doxorubicin—uterine cancer	6.78e-05	0.000295	CcSEcCtD
Lansoprazole—Tinnitus—Doxorubicin—uterine cancer	6.76e-05	0.000294	CcSEcCtD
Lansoprazole—Cardiac disorder—Doxorubicin—uterine cancer	6.73e-05	0.000292	CcSEcCtD
Lansoprazole—Flatulence—Epirubicin—uterine cancer	6.72e-05	0.000292	CcSEcCtD
Lansoprazole—Tension—Epirubicin—uterine cancer	6.7e-05	0.000291	CcSEcCtD
Lansoprazole—Dysgeusia—Epirubicin—uterine cancer	6.68e-05	0.00029	CcSEcCtD
Lansoprazole—Nervousness—Epirubicin—uterine cancer	6.63e-05	0.000288	CcSEcCtD
Lansoprazole—Back pain—Epirubicin—uterine cancer	6.6e-05	0.000287	CcSEcCtD
Lansoprazole—Angiopathy—Doxorubicin—uterine cancer	6.58e-05	0.000286	CcSEcCtD
Lansoprazole—Dizziness—Etoposide—uterine cancer	6.57e-05	0.000285	CcSEcCtD
Lansoprazole—Muscle spasms—Epirubicin—uterine cancer	6.56e-05	0.000285	CcSEcCtD
Lansoprazole—Immune system disorder—Doxorubicin—uterine cancer	6.55e-05	0.000285	CcSEcCtD
Lansoprazole—Mediastinal disorder—Doxorubicin—uterine cancer	6.54e-05	0.000284	CcSEcCtD
Lansoprazole—Chills—Doxorubicin—uterine cancer	6.51e-05	0.000283	CcSEcCtD
Lansoprazole—Arrhythmia—Doxorubicin—uterine cancer	6.48e-05	0.000282	CcSEcCtD
Lansoprazole—Vision blurred—Epirubicin—uterine cancer	6.43e-05	0.000279	CcSEcCtD
Lansoprazole—Alopecia—Doxorubicin—uterine cancer	6.41e-05	0.000278	CcSEcCtD
Lansoprazole—Mental disorder—Doxorubicin—uterine cancer	6.36e-05	0.000276	CcSEcCtD
Lansoprazole—Ill-defined disorder—Epirubicin—uterine cancer	6.33e-05	0.000275	CcSEcCtD
Lansoprazole—Vomiting—Etoposide—uterine cancer	6.32e-05	0.000274	CcSEcCtD
Lansoprazole—Erythema—Doxorubicin—uterine cancer	6.31e-05	0.000274	CcSEcCtD
Lansoprazole—Malnutrition—Doxorubicin—uterine cancer	6.31e-05	0.000274	CcSEcCtD
Lansoprazole—Anaemia—Epirubicin—uterine cancer	6.31e-05	0.000274	CcSEcCtD
Lansoprazole—Agitation—Epirubicin—uterine cancer	6.27e-05	0.000272	CcSEcCtD
Lansoprazole—Rash—Etoposide—uterine cancer	6.26e-05	0.000272	CcSEcCtD
Lansoprazole—Dermatitis—Etoposide—uterine cancer	6.26e-05	0.000272	CcSEcCtD
Lansoprazole—Headache—Etoposide—uterine cancer	6.22e-05	0.00027	CcSEcCtD
Lansoprazole—Flatulence—Doxorubicin—uterine cancer	6.22e-05	0.00027	CcSEcCtD
Lansoprazole—Tension—Doxorubicin—uterine cancer	6.2e-05	0.000269	CcSEcCtD
Lansoprazole—Dysgeusia—Doxorubicin—uterine cancer	6.18e-05	0.000269	CcSEcCtD
Lansoprazole—Malaise—Epirubicin—uterine cancer	6.15e-05	0.000267	CcSEcCtD
Lansoprazole—Nervousness—Doxorubicin—uterine cancer	6.13e-05	0.000266	CcSEcCtD
Lansoprazole—Vertigo—Epirubicin—uterine cancer	6.13e-05	0.000266	CcSEcCtD
Lansoprazole—Syncope—Epirubicin—uterine cancer	6.12e-05	0.000266	CcSEcCtD
Lansoprazole—Leukopenia—Epirubicin—uterine cancer	6.11e-05	0.000265	CcSEcCtD
Lansoprazole—Back pain—Doxorubicin—uterine cancer	6.11e-05	0.000265	CcSEcCtD
Lansoprazole—Muscle spasms—Doxorubicin—uterine cancer	6.07e-05	0.000264	CcSEcCtD
Lansoprazole—Palpitations—Epirubicin—uterine cancer	6.03e-05	0.000262	CcSEcCtD
Lansoprazole—Loss of consciousness—Epirubicin—uterine cancer	6e-05	0.000261	CcSEcCtD
Lansoprazole—Cough—Epirubicin—uterine cancer	5.96e-05	0.000259	CcSEcCtD
Lansoprazole—Vision blurred—Doxorubicin—uterine cancer	5.95e-05	0.000259	CcSEcCtD
Lansoprazole—Convulsion—Epirubicin—uterine cancer	5.91e-05	0.000257	CcSEcCtD
Lansoprazole—Nausea—Etoposide—uterine cancer	5.9e-05	0.000256	CcSEcCtD
Lansoprazole—Hypertension—Epirubicin—uterine cancer	5.89e-05	0.000256	CcSEcCtD
Lansoprazole—Ill-defined disorder—Doxorubicin—uterine cancer	5.86e-05	0.000255	CcSEcCtD
Lansoprazole—Anaemia—Doxorubicin—uterine cancer	5.84e-05	0.000254	CcSEcCtD
Lansoprazole—Myalgia—Epirubicin—uterine cancer	5.81e-05	0.000252	CcSEcCtD
Lansoprazole—Arthralgia—Epirubicin—uterine cancer	5.81e-05	0.000252	CcSEcCtD
Lansoprazole—Chest pain—Epirubicin—uterine cancer	5.81e-05	0.000252	CcSEcCtD
Lansoprazole—Agitation—Doxorubicin—uterine cancer	5.8e-05	0.000252	CcSEcCtD
Lansoprazole—Anxiety—Epirubicin—uterine cancer	5.79e-05	0.000252	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	5.77e-05	0.000251	CcSEcCtD
Lansoprazole—Discomfort—Epirubicin—uterine cancer	5.74e-05	0.000249	CcSEcCtD
Lansoprazole—Malaise—Doxorubicin—uterine cancer	5.69e-05	0.000247	CcSEcCtD
Lansoprazole—Dry mouth—Epirubicin—uterine cancer	5.68e-05	0.000247	CcSEcCtD
Lansoprazole—Vertigo—Doxorubicin—uterine cancer	5.67e-05	0.000246	CcSEcCtD
Lansoprazole—Syncope—Doxorubicin—uterine cancer	5.66e-05	0.000246	CcSEcCtD
Lansoprazole—Leukopenia—Doxorubicin—uterine cancer	5.65e-05	0.000246	CcSEcCtD
Lansoprazole—Confusional state—Epirubicin—uterine cancer	5.62e-05	0.000244	CcSEcCtD
Lansoprazole—Palpitations—Doxorubicin—uterine cancer	5.58e-05	0.000242	CcSEcCtD
Lansoprazole—Oedema—Epirubicin—uterine cancer	5.57e-05	0.000242	CcSEcCtD
Lansoprazole—Anaphylactic shock—Epirubicin—uterine cancer	5.57e-05	0.000242	CcSEcCtD
Lansoprazole—Loss of consciousness—Doxorubicin—uterine cancer	5.55e-05	0.000241	CcSEcCtD
Lansoprazole—Infection—Epirubicin—uterine cancer	5.53e-05	0.00024	CcSEcCtD
Lansoprazole—Cough—Doxorubicin—uterine cancer	5.51e-05	0.000239	CcSEcCtD
Lansoprazole—Shock—Epirubicin—uterine cancer	5.48e-05	0.000238	CcSEcCtD
Lansoprazole—Convulsion—Doxorubicin—uterine cancer	5.47e-05	0.000238	CcSEcCtD
Lansoprazole—Nervous system disorder—Epirubicin—uterine cancer	5.46e-05	0.000237	CcSEcCtD
Lansoprazole—Thrombocytopenia—Epirubicin—uterine cancer	5.45e-05	0.000237	CcSEcCtD
Lansoprazole—Hypertension—Doxorubicin—uterine cancer	5.45e-05	0.000237	CcSEcCtD
Lansoprazole—Tachycardia—Epirubicin—uterine cancer	5.44e-05	0.000236	CcSEcCtD
Lansoprazole—Skin disorder—Epirubicin—uterine cancer	5.41e-05	0.000235	CcSEcCtD
Lansoprazole—Hyperhidrosis—Epirubicin—uterine cancer	5.38e-05	0.000234	CcSEcCtD
Lansoprazole—Chest pain—Doxorubicin—uterine cancer	5.38e-05	0.000234	CcSEcCtD
Lansoprazole—Arthralgia—Doxorubicin—uterine cancer	5.38e-05	0.000234	CcSEcCtD
Lansoprazole—Myalgia—Doxorubicin—uterine cancer	5.38e-05	0.000234	CcSEcCtD
Lansoprazole—Anxiety—Doxorubicin—uterine cancer	5.36e-05	0.000233	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	5.34e-05	0.000232	CcSEcCtD
Lansoprazole—Discomfort—Doxorubicin—uterine cancer	5.31e-05	0.000231	CcSEcCtD
Lansoprazole—Anorexia—Epirubicin—uterine cancer	5.31e-05	0.000231	CcSEcCtD
Lansoprazole—Dry mouth—Doxorubicin—uterine cancer	5.26e-05	0.000228	CcSEcCtD
Lansoprazole—Hypotension—Epirubicin—uterine cancer	5.2e-05	0.000226	CcSEcCtD
Lansoprazole—Confusional state—Doxorubicin—uterine cancer	5.2e-05	0.000226	CcSEcCtD
Lansoprazole—Anaphylactic shock—Doxorubicin—uterine cancer	5.15e-05	0.000224	CcSEcCtD
Lansoprazole—Oedema—Doxorubicin—uterine cancer	5.15e-05	0.000224	CcSEcCtD
Lansoprazole—Infection—Doxorubicin—uterine cancer	5.12e-05	0.000222	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Epirubicin—uterine cancer	5.07e-05	0.00022	CcSEcCtD
Lansoprazole—Shock—Doxorubicin—uterine cancer	5.07e-05	0.00022	CcSEcCtD
Lansoprazole—Nervous system disorder—Doxorubicin—uterine cancer	5.05e-05	0.00022	CcSEcCtD
Lansoprazole—Thrombocytopenia—Doxorubicin—uterine cancer	5.05e-05	0.000219	CcSEcCtD
Lansoprazole—Insomnia—Epirubicin—uterine cancer	5.04e-05	0.000219	CcSEcCtD
Lansoprazole—Tachycardia—Doxorubicin—uterine cancer	5.03e-05	0.000219	CcSEcCtD
Lansoprazole—Skin disorder—Doxorubicin—uterine cancer	5.01e-05	0.000217	CcSEcCtD
Lansoprazole—Paraesthesia—Epirubicin—uterine cancer	5e-05	0.000217	CcSEcCtD
Lansoprazole—Hyperhidrosis—Doxorubicin—uterine cancer	4.98e-05	0.000216	CcSEcCtD
Lansoprazole—Dyspnoea—Epirubicin—uterine cancer	4.97e-05	0.000216	CcSEcCtD
Lansoprazole—Somnolence—Epirubicin—uterine cancer	4.95e-05	0.000215	CcSEcCtD
Lansoprazole—Anorexia—Doxorubicin—uterine cancer	4.91e-05	0.000213	CcSEcCtD
Lansoprazole—Dyspepsia—Epirubicin—uterine cancer	4.9e-05	0.000213	CcSEcCtD
Lansoprazole—Decreased appetite—Epirubicin—uterine cancer	4.84e-05	0.00021	CcSEcCtD
Lansoprazole—Hypotension—Doxorubicin—uterine cancer	4.82e-05	0.000209	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Epirubicin—uterine cancer	4.81e-05	0.000209	CcSEcCtD
Lansoprazole—Fatigue—Epirubicin—uterine cancer	4.8e-05	0.000209	CcSEcCtD
Lansoprazole—Pain—Epirubicin—uterine cancer	4.76e-05	0.000207	CcSEcCtD
Lansoprazole—Constipation—Epirubicin—uterine cancer	4.76e-05	0.000207	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Doxorubicin—uterine cancer	4.7e-05	0.000204	CcSEcCtD
Lansoprazole—Insomnia—Doxorubicin—uterine cancer	4.66e-05	0.000203	CcSEcCtD
Lansoprazole—Paraesthesia—Doxorubicin—uterine cancer	4.63e-05	0.000201	CcSEcCtD
Lansoprazole—Dyspnoea—Doxorubicin—uterine cancer	4.59e-05	0.0002	CcSEcCtD
Lansoprazole—Feeling abnormal—Epirubicin—uterine cancer	4.59e-05	0.000199	CcSEcCtD
Lansoprazole—Somnolence—Doxorubicin—uterine cancer	4.58e-05	0.000199	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Epirubicin—uterine cancer	4.55e-05	0.000198	CcSEcCtD
Lansoprazole—Dyspepsia—Doxorubicin—uterine cancer	4.54e-05	0.000197	CcSEcCtD
Lansoprazole—Decreased appetite—Doxorubicin—uterine cancer	4.48e-05	0.000195	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Doxorubicin—uterine cancer	4.45e-05	0.000193	CcSEcCtD
Lansoprazole—Fatigue—Doxorubicin—uterine cancer	4.44e-05	0.000193	CcSEcCtD
Lansoprazole—Urticaria—Epirubicin—uterine cancer	4.42e-05	0.000192	CcSEcCtD
Lansoprazole—Pain—Doxorubicin—uterine cancer	4.41e-05	0.000191	CcSEcCtD
Lansoprazole—Constipation—Doxorubicin—uterine cancer	4.41e-05	0.000191	CcSEcCtD
Lansoprazole—Body temperature increased—Epirubicin—uterine cancer	4.4e-05	0.000191	CcSEcCtD
Lansoprazole—Abdominal pain—Epirubicin—uterine cancer	4.4e-05	0.000191	CcSEcCtD
Lansoprazole—Feeling abnormal—Doxorubicin—uterine cancer	4.25e-05	0.000185	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Doxorubicin—uterine cancer	4.21e-05	0.000183	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—AKR1C1—uterine cancer	4.14e-05	0.000614	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	4.11e-05	0.000609	CbGpPWpGaD
Lansoprazole—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	4.11e-05	0.000609	CbGpPWpGaD
Lansoprazole—Hypersensitivity—Epirubicin—uterine cancer	4.1e-05	0.000178	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism—DCN—uterine cancer	4.1e-05	0.000608	CbGpPWpGaD
Lansoprazole—Urticaria—Doxorubicin—uterine cancer	4.09e-05	0.000178	CcSEcCtD
Lansoprazole—Abdominal pain—Doxorubicin—uterine cancer	4.07e-05	0.000177	CcSEcCtD
Lansoprazole—Body temperature increased—Doxorubicin—uterine cancer	4.07e-05	0.000177	CcSEcCtD
Lansoprazole—Asthenia—Epirubicin—uterine cancer	4e-05	0.000174	CcSEcCtD
Lansoprazole—Pruritus—Epirubicin—uterine cancer	3.94e-05	0.000171	CcSEcCtD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	3.88e-05	0.000575	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	3.87e-05	0.000574	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—CYP11A1—uterine cancer	3.86e-05	0.000573	CbGpPWpGaD
Lansoprazole—Diarrhoea—Epirubicin—uterine cancer	3.81e-05	0.000166	CcSEcCtD
Lansoprazole—Hypersensitivity—Doxorubicin—uterine cancer	3.8e-05	0.000165	CcSEcCtD
Lansoprazole—ABCG2—Metabolism—STAR—uterine cancer	3.79e-05	0.000561	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—AKR1B1—uterine cancer	3.79e-05	0.000561	CbGpPWpGaD
Lansoprazole—CYP1A1—PPARA activates gene expression—EP300—uterine cancer	3.76e-05	0.000557	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—VEGFA—uterine cancer	3.71e-05	0.000549	CbGpPWpGaD
Lansoprazole—Asthenia—Doxorubicin—uterine cancer	3.7e-05	0.000161	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—RRM2—uterine cancer	3.69e-05	0.000547	CbGpPWpGaD
Lansoprazole—Dizziness—Epirubicin—uterine cancer	3.68e-05	0.00016	CcSEcCtD
Lansoprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—uterine cancer	3.68e-05	0.000545	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	3.67e-05	0.000544	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	3.67e-05	0.000544	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—AKR1C3—uterine cancer	3.65e-05	0.000541	CbGpPWpGaD
Lansoprazole—Pruritus—Doxorubicin—uterine cancer	3.65e-05	0.000158	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—DCN—uterine cancer	3.58e-05	0.000531	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—NDUFB11—uterine cancer	3.54e-05	0.000525	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—SRD5A2—uterine cancer	3.54e-05	0.000525	CbGpPWpGaD
Lansoprazole—Vomiting—Epirubicin—uterine cancer	3.54e-05	0.000154	CcSEcCtD
Lansoprazole—Diarrhoea—Doxorubicin—uterine cancer	3.53e-05	0.000153	CcSEcCtD
Lansoprazole—Rash—Epirubicin—uterine cancer	3.51e-05	0.000153	CcSEcCtD
Lansoprazole—Dermatitis—Epirubicin—uterine cancer	3.51e-05	0.000152	CcSEcCtD
Lansoprazole—Headache—Epirubicin—uterine cancer	3.49e-05	0.000152	CcSEcCtD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	3.46e-05	0.000512	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.44e-05	0.00051	CbGpPWpGaD
Lansoprazole—Dizziness—Doxorubicin—uterine cancer	3.41e-05	0.000148	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—CYP11A1—uterine cancer	3.38e-05	0.0005	CbGpPWpGaD
Lansoprazole—Nausea—Epirubicin—uterine cancer	3.31e-05	0.000144	CcSEcCtD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	3.3e-05	0.000488	CbGpPWpGaD
Lansoprazole—Vomiting—Doxorubicin—uterine cancer	3.28e-05	0.000142	CcSEcCtD
Lansoprazole—CYP1B1—Metabolism—POLD1—uterine cancer	3.27e-05	0.000484	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.25e-05	0.000482	CbGpPWpGaD
Lansoprazole—Rash—Doxorubicin—uterine cancer	3.25e-05	0.000141	CcSEcCtD
Lansoprazole—CYP2C8—Metabolism—SRD5A2—uterine cancer	3.25e-05	0.000482	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—NDUFB11—uterine cancer	3.25e-05	0.000482	CbGpPWpGaD
Lansoprazole—Dermatitis—Doxorubicin—uterine cancer	3.25e-05	0.000141	CcSEcCtD
Lansoprazole—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	3.25e-05	0.000481	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	3.24e-05	0.000479	CbGpPWpGaD
Lansoprazole—Headache—Doxorubicin—uterine cancer	3.23e-05	0.00014	CcSEcCtD
Lansoprazole—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	3.2e-05	0.000474	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—AKR1C3—uterine cancer	3.19e-05	0.000473	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.16e-05	0.000468	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	3.15e-05	0.000467	CbGpPWpGaD
Lansoprazole—Nausea—Doxorubicin—uterine cancer	3.06e-05	0.000133	CcSEcCtD
Lansoprazole—CYP1B1—Metabolism—AKR1C1—uterine cancer	3.05e-05	0.000453	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.98e-05	0.000442	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—POLD1—uterine cancer	2.97e-05	0.00044	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—NDUFB11—uterine cancer	2.9e-05	0.00043	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—SRD5A2—uterine cancer	2.9e-05	0.00043	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—CYP19A1—uterine cancer	2.84e-05	0.000421	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—STK11—uterine cancer	2.84e-05	0.000421	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—SRD5A2—uterine cancer	2.83e-05	0.000419	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—NDUFB11—uterine cancer	2.83e-05	0.000419	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.82e-05	0.000417	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—AKR1C1—uterine cancer	2.78e-05	0.000412	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	2.73e-05	0.000405	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—RRM2—uterine cancer	2.72e-05	0.000403	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	2.69e-05	0.000399	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.67e-05	0.000395	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—NDUFB11—uterine cancer	2.67e-05	0.000395	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—SRD5A2—uterine cancer	2.67e-05	0.000395	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.66e-05	0.000394	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—NDUFB11—uterine cancer	2.64e-05	0.000392	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—SRD5A2—uterine cancer	2.64e-05	0.000392	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—DCN—uterine cancer	2.64e-05	0.000392	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.57e-05	0.000381	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—AKR1B1—uterine cancer	2.56e-05	0.00038	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—STAR—uterine cancer	2.56e-05	0.00038	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.54e-05	0.000377	CbGpPWpGaD
Lansoprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—uterine cancer	2.54e-05	0.000376	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.53e-05	0.000375	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CYP11A1—uterine cancer	2.49e-05	0.000369	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—STK11—uterine cancer	2.48e-05	0.000368	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—CYP19A1—uterine cancer	2.48e-05	0.000368	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—RRM2—uterine cancer	2.48e-05	0.000367	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.43e-05	0.000359	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—DCN—uterine cancer	2.4e-05	0.000356	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	2.38e-05	0.000352	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—AKR1C3—uterine cancer	2.35e-05	0.000348	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—AKR1B1—uterine cancer	2.35e-05	0.000348	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—STAR—uterine cancer	2.35e-05	0.000348	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.32e-05	0.000344	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CYP11A1—uterine cancer	2.26e-05	0.000336	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NDUFB11—uterine cancer	2.26e-05	0.000335	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—SRD5A2—uterine cancer	2.26e-05	0.000335	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	2.2e-05	0.000326	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.2e-05	0.000325	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—AKR1C3—uterine cancer	2.14e-05	0.000317	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—MTHFR—uterine cancer	2.14e-05	0.000317	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—STAR—uterine cancer	2.1e-05	0.000311	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—AKR1B1—uterine cancer	2.1e-05	0.000311	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	2.08e-05	0.000308	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.07e-05	0.000307	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.07e-05	0.000307	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—AKR1B1—uterine cancer	2.05e-05	0.000303	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—STAR—uterine cancer	2.05e-05	0.000303	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	2.03e-05	0.0003	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—POLD1—uterine cancer	2.01e-05	0.000298	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	1.93e-05	0.000286	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—AKR1B1—uterine cancer	1.93e-05	0.000286	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—STAR—uterine cancer	1.93e-05	0.000286	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—AKR1B1—uterine cancer	1.91e-05	0.000283	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—STAR—uterine cancer	1.91e-05	0.000283	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.89e-05	0.00028	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.88e-05	0.000279	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—AKR1C1—uterine cancer	1.88e-05	0.000279	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—MTHFR—uterine cancer	1.87e-05	0.000277	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—POLD1—uterine cancer	1.84e-05	0.000273	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—STK11—uterine cancer	1.83e-05	0.000271	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CYP19A1—uterine cancer	1.83e-05	0.000271	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	1.83e-05	0.000271	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.74e-05	0.000258	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.74e-05	0.000258	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—AKR1C1—uterine cancer	1.72e-05	0.000256	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.72e-05	0.000255	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—RRM2—uterine cancer	1.68e-05	0.000248	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—STK11—uterine cancer	1.67e-05	0.000247	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CYP19A1—uterine cancer	1.67e-05	0.000247	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—POLD1—uterine cancer	1.65e-05	0.000244	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.64e-05	0.000243	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—AKR1B1—uterine cancer	1.63e-05	0.000242	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—STAR—uterine cancer	1.63e-05	0.000242	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—DCN—uterine cancer	1.63e-05	0.000241	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.61e-05	0.000239	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—POLD1—uterine cancer	1.61e-05	0.000238	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.56e-05	0.00023	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—AKR1C1—uterine cancer	1.54e-05	0.000228	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—RRM2—uterine cancer	1.54e-05	0.000228	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CYP11A1—uterine cancer	1.53e-05	0.000227	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—POLD1—uterine cancer	1.51e-05	0.000224	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—AKR1C1—uterine cancer	1.5e-05	0.000223	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—POLD1—uterine cancer	1.5e-05	0.000222	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—DCN—uterine cancer	1.49e-05	0.000221	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—AKR1C3—uterine cancer	1.45e-05	0.000215	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.43e-05	0.000212	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—AKR1C1—uterine cancer	1.42e-05	0.00021	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CYP11A1—uterine cancer	1.41e-05	0.000208	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—AKR1C1—uterine cancer	1.4e-05	0.000208	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.38e-05	0.000205	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—MTHFR—uterine cancer	1.38e-05	0.000204	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—RRM2—uterine cancer	1.37e-05	0.000203	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—RRM2—uterine cancer	1.34e-05	0.000198	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—DCN—uterine cancer	1.33e-05	0.000197	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—AKR1C3—uterine cancer	1.33e-05	0.000197	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—DCN—uterine cancer	1.3e-05	0.000193	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—POLD1—uterine cancer	1.28e-05	0.00019	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—RRM2—uterine cancer	1.26e-05	0.000187	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—STAR—uterine cancer	1.26e-05	0.000187	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—AKR1B1—uterine cancer	1.26e-05	0.000187	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYP11A1—uterine cancer	1.25e-05	0.000186	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—MTHFR—uterine cancer	1.25e-05	0.000186	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—RRM2—uterine cancer	1.25e-05	0.000185	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—DCN—uterine cancer	1.22e-05	0.000182	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYP11A1—uterine cancer	1.22e-05	0.000181	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—DCN—uterine cancer	1.21e-05	0.00018	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.21e-05	0.00018	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—AKR1C1—uterine cancer	1.2e-05	0.000178	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PTEN—uterine cancer	1.19e-05	0.000176	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—AKR1C3—uterine cancer	1.18e-05	0.000176	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.17e-05	0.000173	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—AKR1C3—uterine cancer	1.16e-05	0.000171	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP11A1—uterine cancer	1.15e-05	0.000171	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP11A1—uterine cancer	1.14e-05	0.00017	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—EP300—uterine cancer	1.13e-05	0.000168	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—STK11—uterine cancer	1.13e-05	0.000167	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CYP19A1—uterine cancer	1.13e-05	0.000167	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—AKR1C3—uterine cancer	1.09e-05	0.000161	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—AKR1C3—uterine cancer	1.08e-05	0.00016	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—RRM2—uterine cancer	1.07e-05	0.000158	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.06e-05	0.000157	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PTEN—uterine cancer	1.04e-05	0.000154	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—DCN—uterine cancer	1.04e-05	0.000154	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—STK11—uterine cancer	1.03e-05	0.000153	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CYP19A1—uterine cancer	1.03e-05	0.000153	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.01e-05	0.00015	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—EP300—uterine cancer	9.91e-06	0.000147	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—POLD1—uterine cancer	9.89e-06	0.000147	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP11A1—uterine cancer	9.78e-06	0.000145	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	9.71e-06	0.000144	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	9.26e-06	0.000137	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—AKR1C1—uterine cancer	9.26e-06	0.000137	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—AKR1C3—uterine cancer	9.23e-06	0.000137	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—STK11—uterine cancer	9.23e-06	0.000137	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYP19A1—uterine cancer	9.23e-06	0.000137	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYP19A1—uterine cancer	9.01e-06	0.000134	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—STK11—uterine cancer	9.01e-06	0.000134	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	8.66e-06	0.000128	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP19A1—uterine cancer	8.49e-06	0.000126	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—STK11—uterine cancer	8.49e-06	0.000126	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—MTHFR—uterine cancer	8.48e-06	0.000126	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—STK11—uterine cancer	8.42e-06	0.000125	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP19A1—uterine cancer	8.42e-06	0.000125	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PIK3CA—uterine cancer	8.38e-06	0.000124	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	8.26e-06	0.000122	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—RRM2—uterine cancer	8.25e-06	0.000122	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—DCN—uterine cancer	8.01e-06	0.000119	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.9e-06	0.000117	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—MTHFR—uterine cancer	7.77e-06	0.000115	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PTEN—uterine cancer	7.66e-06	0.000113	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP11A1—uterine cancer	7.54e-06	0.000112	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.53e-06	0.000112	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.47e-06	0.000111	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PIK3CA—uterine cancer	7.33e-06	0.000109	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—EP300—uterine cancer	7.3e-06	0.000108	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—STK11—uterine cancer	7.19e-06	0.000107	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP19A1—uterine cancer	7.19e-06	0.000107	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—AKR1C3—uterine cancer	7.12e-06	0.000106	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PTEN—uterine cancer	6.97e-06	0.000103	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—MTHFR—uterine cancer	6.94e-06	0.000103	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	6.85e-06	0.000101	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—AKT1—uterine cancer	6.85e-06	0.000101	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—MTHFR—uterine cancer	6.77e-06	0.0001	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.75e-06	0.0001	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—EP300—uterine cancer	6.64e-06	9.84e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.44e-06	9.54e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—MTHFR—uterine cancer	6.38e-06	9.45e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—MTHFR—uterine cancer	6.32e-06	9.37e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	6.11e-06	9.06e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—AKT1—uterine cancer	5.99e-06	8.87e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.57e-06	8.26e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP19A1—uterine cancer	5.55e-06	8.23e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—STK11—uterine cancer	5.55e-06	8.23e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—MTHFR—uterine cancer	5.4e-06	8.01e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CA—uterine cancer	5.4e-06	8e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CA—uterine cancer	4.91e-06	7.28e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.76e-06	7.06e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PTEN—uterine cancer	4.72e-06	6.99e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—EP300—uterine cancer	4.5e-06	6.66e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—AKT1—uterine cancer	4.41e-06	6.54e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PTEN—uterine cancer	4.32e-06	6.41e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—MTHFR—uterine cancer	4.17e-06	6.18e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—EP300—uterine cancer	4.12e-06	6.11e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—AKT1—uterine cancer	4.01e-06	5.95e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PTEN—uterine cancer	3.86e-06	5.72e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PTEN—uterine cancer	3.77e-06	5.58e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—EP300—uterine cancer	3.68e-06	5.45e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—EP300—uterine cancer	3.59e-06	5.32e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PTEN—uterine cancer	3.55e-06	5.26e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PTEN—uterine cancer	3.52e-06	5.21e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—EP300—uterine cancer	3.38e-06	5.02e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—EP300—uterine cancer	3.36e-06	4.97e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CA—uterine cancer	3.33e-06	4.93e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CA—uterine cancer	3.05e-06	4.52e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PTEN—uterine cancer	3.01e-06	4.46e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—EP300—uterine cancer	2.87e-06	4.25e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CA—uterine cancer	2.72e-06	4.03e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—AKT1—uterine cancer	2.72e-06	4.03e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CA—uterine cancer	2.66e-06	3.94e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CA—uterine cancer	2.5e-06	3.71e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—AKT1—uterine cancer	2.49e-06	3.69e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CA—uterine cancer	2.48e-06	3.68e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PTEN—uterine cancer	2.32e-06	3.44e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—AKT1—uterine cancer	2.22e-06	3.3e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—EP300—uterine cancer	2.21e-06	3.28e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—AKT1—uterine cancer	2.17e-06	3.22e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CA—uterine cancer	2.12e-06	3.14e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—AKT1—uterine cancer	2.05e-06	3.03e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—AKT1—uterine cancer	2.03e-06	3e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—AKT1—uterine cancer	1.73e-06	2.57e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.64e-06	2.43e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—AKT1—uterine cancer	1.34e-06	1.98e-05	CbGpPWpGaD
